Agata Makówka

Dr. Agata Makówka

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2025 in Breast Cancer: Basic and Clinical Research
Verified
Journal Article
Open access
BKBeata Kotowicz
Beata Kotowicz
MFMalgorzata Fuksiewicz
Malgorzata Fuksiewicz
MJMagdalena Jodkiewicz
Magdalena Jodkiewicz
AMAgata Makówka
Agata Makówka
AJAgnieszka Jagiełło-Gruszfeld
Agnieszka Jagiełło-Gruszfeld
Introduction: The purpose of this study was to determine the prognostic utility of vitamin D concentrations and BMI (body mass index) values and the systemic immune-inflammation index (SII), the systemic inflammation response index (SIRI) and the pan-immune-inflammation value (PIV) to predict the achievement of a complete response to neoadjuvant treatment (NAT) in patients with breast cancer. The correlations between systemic inflammatory response indices and vitamin D concentrations and BMI values were also analysed. Material and Methods: The study included 96 patients with breast cancer, prior to the start of NAT, of which 51 patients were diagnosed with triple-negative breast cancer (TNBC) and 45 patients with human epidermal growth factor receptor type 2 (HER2)-positive type. Results: The SIRI and PIV indices were shown to be significantly higher in patients with TNBC ( P = .001; P = .001) than in patients with HER2. There were no statistical differences in SII, SIRI, PIV, BMI, and vitamin D, according to the response to NAT treatment (pCR vs non-pCR). In the HER2+ group without pCR after NAT, there was a positive correlation of the SII coefficient with BMI values ( R = .41; P = .045). Furthermore, in the entire HER2+ group (irrespective of the NAT response), SII values were negatively correlated with vitamin D levels ( R = −0.39; P = .008). Conclusions: In patients with breast cancer, high SIRI and PIV values may indicate the biological subtype of TNBC. In the HER2+ group, higher SII values were associated with low vitamin D concentrations and elevated BMI.

14 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AMAgata Makówka
Agata Makówka
MFMalgorzata Fuksiewicz
Malgorzata Fuksiewicz
ABAnna Bałata
Anna Bałata
ABAnna Borowiec
Anna Borowiec
KPKatarzyna Pogoda
Katarzyna Pogoda
BKBeata Kotowicz
Beata Kotowicz
Objectives: The aim of the present study was to assess the clinical value of measuring the concentration of neurofilament light chains (NF-Ls) in the diagnosis of taxane-induced neuropathy (CIPN) during neoadjuvant chemotherapy (NAC) in breast cancer patients. Methods: This study included a total of 94 patients who qualified for NAC with taxanes. Serum samples were collected before starting NAC, after three and six cycles, and 3–6 months after NAC. The NF-L concentration was determined using the Ella technology. The assessment of CIPN was based on the clinical symptoms included in the EORTC QLQ-CIPN20 scores. Results: The median NF-L concentrations increased during NAT monitoring. After the end of therapy, a significant decrease in NF-L concentrations was observed (p = 0.001, R = 0.37). We established a cut-off point of 29.5 pg/mL to distinguish between the control group and patients with early symptoms of neuropathy (CIPN G1) (p = 0.001; AUC = 0.982). We showed that NF-L concentrations, regardless of the stage of therapy, increased with the severity of neuropathy symptoms (CIPG1 vs. G2 vs. G3) (p = 0.0189, R = 0.33). According to the established cut-off points, serum NF-L concentrations above 196 pg/mL in patients undergoing therapy likely indicate the presence of low-grade neuropathy (p = 0.0076), while values above 218 pg/mL may indicate advanced CIPN (p = 0.0008). Conclusions: In this study, we demonstrated the usefulness of NF-L levels to confirm neuropathy early in the course of treatment, which is important as the questionnaire-based assessment of neuropathy currently used in practice remains subjective. Ultimately, serum NF-L levels are helpful in determining the severity of NAC-induced neuropathy among breast cancer patients.

23 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BPBeata Puton
Beata Puton
AMAgata Makówka
Agata Makówka
ABAnna Borowiec
Anna Borowiec
POPatrycja Ozdowska
Patrycja Ozdowska
AŻAgnieszka Maria Żebrowska
Agnieszka Maria Żebrowska
BKBeata Kotowicz
Beata Kotowicz
Background/Objectives: Cancer therapy-related cardiac dysfunction (CTRCD) is a clinically important complication of anthracycline-based chemotherapy, and early identification of patients at increased risk remains challenging. Apolipoproteins involved in lipid metabolism and inflammatory pathways may reflect cardiovascular alterations induced by anticancer treatment. This study aimed to evaluate changes in selected apolipoproteins and C-reactive protein (CRP) during anthracycline therapy and to assess their association with the development of CTRCD in patients with breast cancer. Methods: This prospective study included 54 patients with breast cancer treated with anthracycline-based chemotherapy at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Plasma concentrations of apolipoproteins A1, A2, B, C1, C3, D, E, H, and J, as well as CRP, were measured using an xMAP multiplex assay at baseline, after completion of chemotherapy, and approximately 6 months after treatment. Cardiac biomarkers, including high-sensitivity cardiac troponin T (hs-cTnT) and NT-proBNP, were also assessed. CTRCD was diagnosed based on standard clinical and echocardiographic criteria. Results: Anthracycline therapy significantly affected the apolipoprotein profile, with decreased concentrations of apolipoproteins A1, A2, B, C1, E, H, and J, and increased concentrations of apolipoproteins C3 (ApoC3) and D and CRP during follow-up (all p < 0.001). Patients with CTRCD showed higher concentrations of selected apolipoproteins, particularly apolipoproteins C3, E (ApoE) and A2. The change in ApoC3 concentration from baseline to 6 months demonstrated the strongest predictive performance for CTRCD (AUC = 0.875; 95% CI: 0.735–1.000; p < 0.001). A cut-off value of ≥31.50 mg/dL provided 83.3% sensitivity and 87.5% specificity. Conclusions: Changes in apolipoprotein concentrations, particularly an increase in ApoC3 during anthracycline therapy, may be associated with the development of CTRCD. Assessment of ApoC3 and ApoE after chemotherapy may provide additional information for identifying breast cancer patients at higher risk of cardiac dysfunction.